ABIVAX: Share capital and voting rights as of November 30, 2024

On December 18, 2024, ABIVAX, a company listed on Euronext Paris, published information regarding its share capital and associated voting rights. As of November 30, 2024, the company's share capital amounted to €633,478.37, divided into 63,347,837 shares. The theoretical voting rights, used as a basis for threshold crossing calculations, were 70,991,061, which also corresponds to the number of exercisable voting rights.

These figures are in line with Article L. 233-8 II of the French Commercial Code and Article 223-16 of the AMF Regulation, ensuring transparency towards shareholders and the public. This information is crucial for the company's investors and stakeholders, providing a clear view of the ownership structure and potential influence at general meetings. Abivax continues to develop its lead drug candidate, obefazimod, which is currently in the clinical treatment phase.